Fundraising Fox

Convergent Therapeutics

Cambridge, US · Founded 2020 · Delaware corporation · 3 known investors

Biotech

Founders & leadership

Convergent Therapeutics was founded in 2020 by Philip Kantoff and Neil Bander.

PK
Philip KantoffCo-founder
NB
Neil BanderCo-founder
ES
Eric SullivanExecutive
AB
Alexander BrownExecutive

Board

JSJake Simson
Jake SimsoninBoard directorPartner at RA Capital
TZ
Tal ZaksBoard director
JT
Jim TrenkleBoard director

Investors · 3

InvusreportedNew York
OrbiMedreported · 2 sourcesNew York · $1M – $75M
RA Capitalreported · 3 sourcesBostonvia Jake Simson · board

Reported raises · per SEC filings

Form D private placements

$51.4M disclosed across 2 rounds · 2023–2024

▶$22.2MraisedAug 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SullivanExecutive Officer
  • Jake SimsonDirector
  • Tal ZaksDirector
  • Jim TrenkleDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Neil BanderExecutive Officer, Director
Offering amount
$40M
Amount sold
$22.2M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.2MraisedMay 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil BanderDirector
  • Jake SimsonDirector
  • Philip KantoffExecutive Officer, Director
  • Alexander BrownExecutive Officer
  • Tal ZaksDirector
Offering amount
$99.2M
Amount sold
$29.2M
First sale
Apr 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data - AOLaol.com · Aug 2026Convergent raises $90M to develop its radiopharmaceutical for prostate cancer | BioPharma Divebiopharmadive.com · May 2023Radioantibody startup led by prostate cancer experts raises $90M - Convergent Therapeuticsconvergentrx.com · May 2023Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumorsprnewswire.com · May 2023Radiopharmaceutical company Convergent closes series A to the tune of $90Mfiercebiotech.com · May 2023Convergent Therapeutics Raises $90M in Series A Fundingfinsmes.com · May 2023

Frequently asked questions

Who founded Convergent Therapeutics?
Convergent Therapeutics was founded by Philip Kantoff, Neil Bander in 2020.
Who are Convergent Therapeutics's investors?
Convergent Therapeutics's investors include Invus, OrbiMed, RA Capital.
How much funding has Convergent Therapeutics raised?
Convergent Therapeutics has disclosed $51.4M raised across 2 rounds.
Where is Convergent Therapeutics headquartered?
Convergent Therapeutics is headquartered in Cambridge, US.